In what is claimed “a world first” by the Department of Health and Ageing, Australian schoolboys will be able to get treatment with Gardasil (human papillomavirus quadrivalent [types 6, 11, 16, and 18] vaccine, recombinant, from Merck & Co), which will protect them against developing a range of cancers and bolster the effectiveness of this vaccine in women.
Starting next school year, the Gillard government will fund the vaccine for 12 and 13-year-old boys through school-based programs under the National Immunization Program. Year 9 boys will also be able to get the vaccine at school under a catch-up program for the next two years.
Minister for Health Tanya Plibersek said providing the HPV vaccine to boys would protect them and increase the effectiveness of the vaccination program for girls, stating: “Every parent wants their child to be healthy and that is why the Australian government is delivering the best protection we have against HPV related cancer through this vaccine. By building on Australia’s world-class immunization program, we’re stopping preventable HPV related disease and cancers, and that makes a difference to the quality of life of our families.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze